Article discusses results demonstrating parenteral support (PS) reduction ranging from 12 to 37% in ongoing proof-of-concept study of crofelemer in pediatric patients with intestinal failure Associated with significant toxicities to patients, PS has a lethal natural history, and PS reduction can potentially extend and save lives SAN FRANCISCO, CA / ACCESS Newswire / January 6, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that an article published December 29, 2025 in HEALTH, a bi-monthl ...

Alumis (NasdaqGS:ALMS) Update / Briefing January 06, 2026 08:00 AM ET Company ParticipantsJohn Schroer - CFODerek Archila - Managing Director and Co-Head of Therapeutics ResearchMartin Babler - CEOJörn Drappa - CMOConference Call ParticipantsBrian Skorney - Senior Research AnalystYatin Suneja - Senior Managing Director and Biotechnology AnalystThomas Smith - Senior Research AnalystMitchell Kapoor - Director and Senior Biotechnology AnalystJeff Jones - Managing Director and Senior AnalystTerence Flynn - Equi ...

Johnson & Johnson (JNJ) announced on Tuesday that nipocalimab, its experimental therapy for an autoimmune condition called systemic lupus erythematosus, reached the main goal of a mid-stage trial. Based on topline data, the New Brunswick, New Jersey-based pharma giant said that its ...

Biodexa Pharmaceuticals (BDRX) announced the promotion of Fiona Sharp to CFO and Company Secretary along with her election to the Board of Directors of the Company with immediate effect. Sharp is a senior finance professional having joined the Company as Group Financial Controller in December 2019. During her tenure, she has consistently broadened her remit to include many of the responsibilities of a CFO. Stephen Stamp will relinquish his roles as CFO and Company Secretary but remain as CEO. Claim 70% O ...

Core Viewpoint - LENZ Therapeutics has entered into an exclusive distribution agreement with Lunatus to register and commercialize VIZZ for the treatment of presbyopia in the Middle East region, marking a significant expansion of its commercial partnerships outside the United States [1] Group 1: Agreement Details - The agreement allows Lunatus to retain exclusive commercialization rights for VIZZ in several Middle Eastern countries, including the United Arab Emirates, Saudi Arabia, Kuwait, Qatar, Bahrain, Oman, Jordan, Lebanon, and Iraq [1] - LENZ Therapeutics will receive upfront, regulatory, and commercial milestone payments, along with a significant share of revenue generated in the region through a pre-determined minimum product supply price [1] Group 2: Product Information - VIZZ is the first and only FDA-approved aceclidine-based eye drop specifically for the treatment of presbyopia, highlighting its unique position in the market [1] - The commercial launch of VIZZ in the United States is gaining momentum, which supports the strategic expansion into international markets [1] Group 3: Company Strategy - The partnership with Lunatus represents LENZ's fourth commercialization partnership for VIZZ, demonstrating the company's commitment to expanding global access to this presbyopia therapy [1]

Core Insights - The JASMINE study achieved its primary endpoint and key secondary and exploratory endpoints, indicating the potential of nipocalimab for steroid sparing in systemic lupus erythematosus (SLE) [2][4] - Johnson & Johnson plans to initiate a Phase 3 program for nipocalimab based on the positive topline results from the Phase 2b study [2][5] Company Overview - Johnson & Johnson is focused on innovative medicine and aims to address complex diseases through advanced healthcare solutions [11] - The company has a strong commitment to developing treatments that are safe, tolerable, and capable of reducing disease activity while preserving immune function [5] Industry Context - SLE is a chronic autoimmune disease affecting approximately 3 to 5 million people globally, with around 450,000 cases in the U.S. [3][9] - The disease significantly impacts health-related quality of life, with symptoms including severe fatigue, joint pain, and rashes [9] - There is a critical need for new immunoselective therapies due to complications associated with long-term steroid use in SLE patients [5]

POTOMAC, MD / ACCESS Newswire / January 6, 2026 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage pharmaceutical company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer's disease, today announced that its Board of Directors has approved a change in the Company's fiscal year end from March 31 to December 31, effective December 31, 2025. "This is a straightforward but important step in strengthening how we engage with U.S. i ...

MIAMI, FL, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) (“ETST” or the “Company”), a strategic holding company, is issuing a formal directive to all financial data providers, news aggregators, and brokerage platforms to reconcile their databases with the Company’s established pharmaceutical operations. Following a fundamental strategic pivot initiated in 2022, the Company has fully transitioned away from legacy industries and is now operating within the healthcare and pharmaceutica ...

Completed enrollment in DENALI Part 2a; dose confirmation expected in 1H 2026DENALI Part 2 trial topline readout expected by year end 2026; potential to support accelerated approvalInitiation of the ASPENOVA Phase 3, randomized, confirmatory trial planned in 1H 2026 SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatm ...

Envudeucitinib ONWARD1 and ONWARD2 Phase 3 Topline Readout Analyst and Investor Webcast – January 6, 2026 1 Forward-Looking Statements This presentation contains forward looking statements within the meaning of federal securities laws, including the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon current plans, estimates and expectations of management of Alumis Inc. ("Alumis") in light of historical results and trends, current conditions and p ...